Serendipity Partners (Serendipity) now owns 49% of the shares, however, Dr. Ola Gudmundsen will still hold the majority of the shares.
The transaction is mainly structured as a share issue, where Serendipity provides growth capital to LINK Medical, states the company.
Co-owners and long-term investors
To enable further growth and provide new competencies to the company, Ola Gudmundsen has decided to invite Serendipity as co-owners and long-term investors in LINK Medical.
“More than just capital, they can add knowledge and competence, as Serendipity is run by medical doctors, pharmacists, and others with an extensive experience in pharma or biotech industries.”
“I have known the founders of Serendipity Partners for many years. As an investment fund specializing in life science, and with a base in Oslo, Serendipity Partners is the best partner for us. More than just capital, they can add knowledge and competence, as Serendipity is run by medical doctors, pharmacists, and others with an extensive experience in pharma or biotech industries. For a long time, I have worked with Serendipity to make sure that this partnership is a good fit for us, and we are all very enthusiastic to have found a common platform for cooperation,” says Ola Gudmundsen.
Michael Bodd from Serendipity Partners will be the chairman of the board in LINK Medical. His colleague Christopher Tangen will also join the board, alongside Ola Gudmundsen and Renee Amundsen.
Photo of Ola Gudmundsen and Michael Bodd: Anders Horntvedt